OPUGOTAMIG OLATANSINE
UNII 8R9DRT37YD

Substance Identification & Data

This profile provides standardized clinical and technical data for Opugotamig Olatansine, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 8R9DRT37YD.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2779564-40-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

8R9DRT37YD

CAS Registry Number

2779564-40-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

OPUGOTAMIG OLATANSINE

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C191851

National Cancer Institute reference terminology for clinical and research data.

INN ID

12957

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Opugotamig Olatansine

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Opugotamig Olatansine. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Opugotamig Olatansine

Common Names & Synonyms

Immunoglobulin, anti-(human folate receptor α) (human-Mus musculus monoclonal FR1-57 single-chain Fv fragment VL-(GGGGS)4-VH)fusion protein with peptide linker (GS) fusion protein with immunoglobulin G1 [4-serine,151-tryptophan,de-232-lysine] (human γ1-chain C region C-terminal fragment), (259→227′),(262→230′)-bis(disulfide) with immunoglobulin G1 anti-(human folate receptor α) [367-serine,369-alanine,408-valine,de-448-lysine] (human-Mus musculus monoclonal Mov-19 γ1-chain) disulfide with human-Mus musculus monoclonal Mov-19 κ-chain, N6-amide with N2′-[6-[[[[N-[4-[[1-(3-carboxypropyl)-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxobutyl]-L-alanyl-D-alanyl-L-alanyl]amino]methyl]thio]-1-oxohexyl]-N2′-deacetylmaytansine

immunoglobulin (G1_L-kappa)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens FOLR1 (folate receptor 1, folate receptor alpha, FRalpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], biparatopic, assymetric, bivalent; conjugated, on an average of 3 to 4 lysinyl residues to olatansine scFvkh-G1(h-CH2-CH3) heavy chain, anti-FOLR1 (1''-479'') [V-KAPPA (Mus musculus IGKV5-43*01 (86.3%) -IGKJ2*03 (91.7%) S120>C (101''), CDR-IMGT [6.3.10] (27''-32''.50''-52''.89''-98'')) (1''-108'')-20-mer tetrakis(tetraglycyl-seryl) linker (109''-128'') -VH (Mus musculus IGHV5-17*02 (88.8%) -(IGHD) -IGHJ3*01 (91.7%) A128>S (246''), CDR-IMGT [8.8.11] (154''-161''.179''-186''.225''-235'')) (129''-246'') -2-mer (glycyl-seryl) linker (247''-248'') -Homo sapiens IGHG1*03 h-CH2-CH3, nG1m1 CH3 E12, M14, G1v37 h S5, G1v32 CH3 W22 (knob) (hinge 1-15 C5>S (253'') (249''-263''), CH2 (264''-373''), CH3 T22>W (399'') (374''-478''), CHS K2>del (479'')) (249''-479'')]; dimer (227-259'': 230-262'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa; substituted at the side chain nitrogen atom of an average of 3 to 4 L-lysinyl residues with radical group 4-[(3RS)-3-{[(2S,14S,17R,20S)-1-{[(14S,16S,2R,32S,33S,4S,10E,12E,14R)-86-chloro-14-hydroxy-85,14-dimethoxy-2,33,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-[1,3]oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl]oxy}-2,3,14,17,20-pentamethyl-1,4,13,16,19,22-hexaoxo-10-thia-3,12,15,18,21-pentaazapentacosan-25-yl]sulfanyl}-2,5-dioxopyrrolidin-1-yl]butanoyl (olatansine)

opugotamig olatansine [INN]